Allogene Therapeutics Inc
NASDAQ:ALLO
Income Statement
Earnings Waterfall
Allogene Therapeutics Inc
Revenue
|
95k
USD
|
Operating Expenses
|
-314.6m
USD
|
Operating Income
|
-314.5m
USD
|
Other Expenses
|
-12.8m
USD
|
Net Income
|
-327.3m
USD
|
Income Statement
Allogene Therapeutics Inc
Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
38
N/A
|
38
+0%
|
38
+0%
|
38
+0%
|
0
-99%
|
0
+25%
|
0
N/A
|
0
-4%
|
0
N/A
|
0
-21%
|
0
-5%
|
0
-47%
|
|
Operating Income | ||||||||||||||||||||||
Operating Expenses |
(183)
|
(217)
|
(127)
|
(163)
|
(198)
|
(223)
|
(240)
|
(253)
|
(258)
|
(272)
|
(280)
|
(290)
|
(294)
|
(303)
|
(308)
|
(313)
|
(336)
|
(355)
|
(359)
|
(339)
|
(315)
|
|
Selling, General & Administrative |
(36)
|
(47)
|
(50)
|
(56)
|
(57)
|
(60)
|
(62)
|
(63)
|
(65)
|
(66)
|
(69)
|
(71)
|
(74)
|
(78)
|
(78)
|
(78)
|
(79)
|
(78)
|
(77)
|
(75)
|
(72)
|
|
Research & Development |
(147)
|
(167)
|
(77)
|
(107)
|
(140)
|
(161)
|
(178)
|
(191)
|
(193)
|
(206)
|
(211)
|
(218)
|
(220)
|
(225)
|
(230)
|
(235)
|
(256)
|
(276)
|
(281)
|
(264)
|
(243)
|
|
Other Operating Expenses |
0
|
(4)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(183)
N/A
|
(217)
-19%
|
(127)
+42%
|
(163)
-28%
|
(198)
-21%
|
(223)
-13%
|
(240)
-8%
|
(253)
-5%
|
(258)
-2%
|
(234)
+9%
|
(242)
-3%
|
(251)
-4%
|
(256)
-2%
|
(303)
-18%
|
(308)
-2%
|
(313)
-2%
|
(335)
-7%
|
(355)
-6%
|
(358)
-1%
|
(339)
+5%
|
(314)
+7%
|
|
Pre-Tax Income | ||||||||||||||||||||||
Interest Income Expense |
2
|
7
|
12
|
18
|
17
|
16
|
14
|
11
|
9
|
6
|
5
|
3
|
2
|
2
|
1
|
2
|
5
|
6
|
10
|
15
|
18
|
|
Non-Reccuring Items |
(31)
|
(30)
|
(32)
|
(10)
|
(5)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(13)
|
|
Total Other Income |
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(2)
|
(3)
|
(3)
|
(3)
|
(1)
|
(2)
|
(2)
|
(3)
|
(6)
|
(9)
|
(18)
|
|
Pre-Tax Income |
(212)
N/A
|
(241)
-14%
|
(147)
+39%
|
(154)
-5%
|
(185)
-20%
|
(208)
-12%
|
(227)
-9%
|
(243)
-7%
|
(250)
-3%
|
(229)
+9%
|
(239)
-4%
|
(251)
-5%
|
(257)
-3%
|
(304)
-18%
|
(308)
-1%
|
(313)
-2%
|
(333)
-6%
|
(351)
-6%
|
(355)
-1%
|
(333)
+6%
|
(327)
+2%
|
|
Net Income | ||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(212)
|
(241)
|
(147)
|
(154)
|
(185)
|
(207)
|
(227)
|
(243)
|
(250)
|
(229)
|
(239)
|
(251)
|
(257)
|
(304)
|
(308)
|
(313)
|
(333)
|
(351)
|
(355)
|
(333)
|
(327)
|
|
Net Income (Common) |
(212)
N/A
|
(241)
-14%
|
(147)
+39%
|
(154)
-5%
|
(185)
-20%
|
(207)
-12%
|
(227)
-10%
|
(243)
-7%
|
(250)
-3%
|
(229)
+9%
|
(239)
-4%
|
(251)
-5%
|
(257)
-3%
|
(304)
-18%
|
(308)
-1%
|
(313)
-2%
|
(333)
-6%
|
(351)
-6%
|
(355)
-1%
|
(333)
+6%
|
(327)
+2%
|
|
EPS (Diluted) |
-1.74
N/A
|
-2.47
-42%
|
-1.47
+40%
|
-1.5
-2%
|
-1.83
-22%
|
-1.9
-4%
|
-1.96
-3%
|
-1.9
+3%
|
-2.08
-9%
|
-1.73
+17%
|
-1.77
-2%
|
-1.82
-3%
|
-1.89
-4%
|
-2.14
-13%
|
-2.14
N/A
|
-2.17
-1%
|
-2.32
-7%
|
-2.44
-5%
|
-2.41
+1%
|
-1.98
+18%
|
-2.09
-6%
|